Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

Impact · against what's priced in

The article provides no catalysts for BNTX or MRNA as its highlights—BioNTech's cash position, buyback, and oncology pipeline—are already fully accounted for in the current stock price. For BMY, the mention of collaboration results is positive but lacks new data to move the needle.

BNTX+0.00: Already priced in
The price assumes: €16.6 billion liquidity position and a $1 billion share buyback

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

What matters in this story

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

What matters in this story

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

How each ticker is affected

Connected tickers

Track these names every morning.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

What matters in this story

Next reads from the same story arc

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

What matters in this story

Next reads from the same story arc

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

How each ticker is affected

Connected tickers

Track these names every morning.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady

Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know